Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials

BACKGROUND: In three 8-week studies of vilazodone 40 mg/d (NCT00285376, NCT00683592, and NCT01473394) and a 10-week study of vilazodone 20 or 40 mg/d (NCT01473381), adults with major depressive disorder (MDD) showed significantly greater improvement with vilazodone versus placebo in global disease s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuropsychiatr Dis Treat
Main Authors: Durgam, Suresh, Chen, Changzheng, Gommoll, Carl P, Edwards, John, Citrome, Leslie
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5144912/
https://ncbi.nlm.nih.gov/pubmed/27980409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S117581
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados